Identification

Name
Isosorbide Dinitrate
Accession Number
DB00883  (APRD00455)
Type
Small Molecule
Groups
Approved
Description

A vasodilator used in the treatment of angina pectoris. Its actions are similar to nitroglycerin but with a slower onset of action. [PubChem]

Structure
Thumb
Synonyms
  • 1,4:3,6-Dianhydrosorbitol 2,5-dinitrate
  • Carvasin
  • D-Isosorbide dinitrate
  • Dianhydrosorbitol 2,5-dinitrate
  • Dinitrate d'isosorbide
  • Dinitrato de isosorbida
  • Dinitroisosorbide
  • Dinitrosorbide
  • Flindix
  • ISDN
  • Isorbid
  • Isosorbide 2,5-dinitrate
  • Isosorbide dinitrate
  • Isosorbidi dinitras
  • Nitrosorbide
  • Sorbide nitrate
  • Sorbidilat
  • Sorbidnitrate
External IDs
C01DA08
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cedocard-SR Srt 20mgTablet, extended release20 mgOralPaladin Labs Inc1987-12-312009-08-07Canada
Cedocard-SR Srt 40mgTablet, extended release40 mgOralPaladin Labs Inc1995-12-312009-08-07Canada
Coradur Tab 20mgTablet, extended release20 mgOralGlaxo Canada Inc1987-12-311997-04-25Canada
CoronexTablet10 mgOralWyeth Ltd.1994-12-312007-01-08Canada
CoronexTablet30 mgOralWyeth Ltd.1994-12-312007-01-08Canada
Coronex 5mg Sublingual TabletsTablet5 mgSublingualWyeth Ltd.1994-12-312007-01-08Canada
Dilatrate SRCapsule40 mg/1OralAuxilium Pharmaceuticals, Inc.2014-10-242015-12-29Us
Dilatrate SRCapsule, extended release40 mg/1OralEndo Pharmaceuticals2012-02-15Not applicableUs
IsdnTablet5 mgSublingualAa Pharma Inc1985-12-31Not applicableCanada
IsdnTablet10 mgOralAa Pharma Inc1982-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IsosorbideTablet20 mg/1OralHikma Pharmaceutical1983-04-26Not applicableUs
IsosorbideTablet20 mg/1OralCardinal Health1987-10-292015-12-29Us
IsosorbideTablet10 mg/1OralCardinal Health1987-10-292015-12-29Us
IsosorbideTablet10 mg/1OralHikma Pharmaceutical1978-12-01Not applicableUs
IsosorbideTablet20 mg/1OralGolden State Medical Supply1987-11-02Not applicableUs
IsosorbideTablet5 mg/1OralHikma Pharmaceutical1978-12-01Not applicableUs
IsosorbideTablet10 mg/1OralMc Kesson Contract Packaging2011-09-22Not applicableUs
IsosorbideTablet5 mg/1OralGolden State Medical Supply1987-10-26Not applicableUs
IsosorbideTablet10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
IsosorbideTablet20 mg/1OralMc Kesson Contract Packaging2011-11-04Not applicableUs
International/Other Brands
Carvasin (Ayerst) / Cedocard retard / Dilatrate-SR (Schwarz) / Flindix (Vitória) / Isoket (Schwarz) / Isorbid (Armstrong) / Isordil (Valeant) / Nitrosorbide (Lusofarmaco) / Sorbidilat (Actavis)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
BiDilIsosorbide Dinitrate (20 mg/1) + Hydralazine hydrochloride (37.5 mg/1)Tablet, film coatedOralRemedy Repack2013-10-082016-04-05Us
BiDilIsosorbide Dinitrate (20 mg/1) + Hydralazine hydrochloride (37.5 mg/1)Tablet, film coatedOralArbor Pharmaceuticals2012-12-05Not applicableUs
BiDilIsosorbide Dinitrate (20 mg/1) + Hydralazine hydrochloride (37.5 mg/1)Tablet, film coatedOralArbor Pharmaceuticals2005-06-23Not applicableUs12948 0001 12 nlmimage10 2f131798
Categories
UNII
IA7306519N
CAS number
87-33-2
Weight
Average: 236.1363
Monoisotopic: 236.028065242
Chemical Formula
C6H8N2O8
InChI Key
MOYKHGMNXAOIAT-JGWLITMVSA-N
InChI
InChI=1S/C6H8N2O8/c9-7(10)15-3-1-13-6-4(16-8(11)12)2-14-5(3)6/h3-6H,1-2H2/t3-,4+,5-,6-/m1/s1
IUPAC Name
(3S,3aS,6R,6aS)-6-(nitrooxy)-hexahydrofuro[3,2-b]furan-3-yl nitrate
SMILES
[H][[email protected]]12OC[[email protected]](O[N+]([O-])=O)[[email protected]@]1([H])OC[[email protected]]2O[N+]([O-])=O

Pharmacology

Indication

For the prevention of angina pectoris due to coronary artery disease.

Structured Indications
Pharmacodynamics

Isosorbide Dinitrate is a moderate to long acting oral organic nitrate used for the relief and prophylactic management of angina pectoris. It relaxes the vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the heart, thereby reducing left ventricular end- diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure.

Mechanism of action

Similar to other nitrites and organic nitrates, isosorbide dinitrate is converted to nitric oxide (NO), an active intermediate compound which activates the enzyme guanylate cyclase (atrial natriuretic peptide receptor A). This stimulates the synthesis of cyclic guanosine 3',5'-monophosphate (cGMP) which then activates a series of protein kinase-dependent phosphorylations in the smooth muscle cells, eventually resulting in the dephosphorylation of the myosin light chain of the smooth muscle fiber. The subsequent release of calcium ions results in the relaxation of the smooth muscle cells and vasodilation.

TargetActionsOrganism
AAtrial natriuretic peptide receptor 1
agonist
Human
Absorption

Absorption of isosorbide dinitrate after oral dosing is nearly complete, but bioavailability is highly variable (10% to 90%), with extensive first-pass metabolism in the liver. The average bioavailability of isosorbide dinitrate is about 25%.

Volume of distribution
  • 2 to 4 L/kg
Protein binding

Very low

Metabolism

Hepatic

Route of elimination
Not Available
Half life

1 hour

Clearance
Not Available
Toxicity

Symptoms of overdose include reduced cardiac output and hypotension.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Acebutolol.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide Dinitrate.Approved
AliskirenThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Aliskiren.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Isosorbide Dinitrate.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Isosorbide Dinitrate.Approved
AmiodaroneThe metabolism of Isosorbide Dinitrate can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Isosorbide Dinitrate.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Isosorbide Dinitrate.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Isosorbide Dinitrate.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Isosorbide Dinitrate.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Isosorbide Dinitrate.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Isosorbide Dinitrate.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Isosorbide Dinitrate.Approved, Investigational
AtazanavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Isosorbide Dinitrate.Approved
AtomoxetineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Atomoxetine.Approved
AvanafilAvanafil may increase the vasodilatory activities of Isosorbide Dinitrate.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Azilsartan medoxomil.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Isosorbide Dinitrate.Experimental
BarbitalBarbital may increase the hypotensive activities of Isosorbide Dinitrate.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Isosorbide Dinitrate.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Isosorbide Dinitrate.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Isosorbide Dinitrate.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Isosorbide Dinitrate.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Isosorbide Dinitrate.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Isosorbide Dinitrate.Approved
BoceprevirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Isosorbide Dinitrate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Isosorbide Dinitrate.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Isosorbide Dinitrate.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Isosorbide Dinitrate.Approved, Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Isosorbide Dinitrate.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Captopril.Approved
CarbamazepineThe metabolism of Isosorbide Dinitrate can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Isosorbide Dinitrate.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Isosorbide Dinitrate.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Carvedilol.Approved, Investigational
CeritinibThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Ceritinib.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isosorbide Dinitrate.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Isosorbide Dinitrate.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Isosorbide Dinitrate.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Isosorbide Dinitrate.Approved, Investigational
ClarithromycinThe metabolism of Isosorbide Dinitrate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Isosorbide Dinitrate.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Isosorbide Dinitrate.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Isosorbide Dinitrate.Approved
ClotrimazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Isosorbide Dinitrate.Approved
CobicistatThe metabolism of Isosorbide Dinitrate can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Isosorbide Dinitrate can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Isosorbide Dinitrate.Investigational
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Isosorbide Dinitrate.Approved, Investigational
DarunavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Delavirdine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Isosorbide Dinitrate.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Isosorbide Dinitrate.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Diclofenamide.Approved
DihydroergotamineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Isosorbide Dinitrate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Dipyridamole.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Isosorbide Dinitrate.Approved
DoxycyclineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Isosorbide Dinitrate can be decreased when combined with Dronedarone.Approved
DuloxetineIsosorbide Dinitrate may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Isosorbide Dinitrate.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Isosorbide Dinitrate.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Isosorbide Dinitrate.Approved
EnzalutamideThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Isosorbide Dinitrate.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Isosorbide Dinitrate.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Isosorbide Dinitrate.Approved
ErythromycinThe metabolism of Isosorbide Dinitrate can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Isosorbide Dinitrate.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Etacrynic acid.Approved
EthanolEthanol may increase the vasodilatory activities of Isosorbide Dinitrate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Felodipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Isosorbide Dinitrate.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Isosorbide Dinitrate.Approved, Investigational
FluconazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Fluconazole.Approved
FluvoxamineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Isosorbide Dinitrate.Approved
FosphenytoinThe metabolism of Isosorbide Dinitrate can be increased when combined with Fosphenytoin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Isosorbide Dinitrate.Approved, Vet Approved
Fusidic AcidThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Fusidic Acid.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Isosorbide Dinitrate.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Isosorbide Dinitrate.Approved
HydralazineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Isosorbide Dinitrate.Approved, Investigational
IdelalisibThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Idelalisib.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Isosorbide Dinitrate.Approved, Investigational
ImatinibThe metabolism of Isosorbide Dinitrate can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Isosorbide Dinitrate.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Isosorbide Dinitrate.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Isosorbide Dinitrate.Approved
IndinavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Indinavir.Approved
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Isosorbide Dinitrate.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Isosorbide Dinitrate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isosorbide Dinitrate.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Isosorbide Dinitrate.Approved, Vet Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Isosorbide Dinitrate.Approved
ItraconazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Isosorbide Dinitrate.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Isosorbide Dinitrate.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Isosorbide Dinitrate.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Isosorbide Dinitrate.Approved, Investigational
LevodopaIsosorbide Dinitrate may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Isosorbide Dinitrate.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Isosorbide Dinitrate.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Isosorbide Dinitrate.Approved, Investigational
LopinavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Lopinavir.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Isosorbide Dinitrate.Approved
LovastatinThe metabolism of Isosorbide Dinitrate can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Isosorbide Dinitrate can be increased when combined with Lumacaftor.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Isosorbide Dinitrate.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Isosorbide Dinitrate.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Isosorbide Dinitrate.Approved
MethohexitalMethohexital may increase the hypotensive activities of Isosorbide Dinitrate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isosorbide Dinitrate.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Isosorbide Dinitrate.Approved
MetipranololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Isosorbide Dinitrate.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Isosorbide Dinitrate.Approved, Investigational
MifepristoneThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Mifepristone.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Isosorbide Dinitrate.Approved
MirodenafilMirodenafil may increase the vasodilatory activities of Isosorbide Dinitrate.Investigational
MitotaneThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Mitotane.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Isosorbide Dinitrate.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Isosorbide Dinitrate.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Isosorbide Dinitrate.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Isosorbide Dinitrate.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Isosorbide Dinitrate.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nadolol.Approved
NebivololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Isosorbide Dinitrate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Isosorbide Dinitrate can be increased when combined with Nevirapine.Approved
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Isosorbide Dinitrate.Approved
NicorandilNicorandil may increase the hypotensive activities of Isosorbide Dinitrate.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nifedipine.Approved
NilotinibThe metabolism of Isosorbide Dinitrate can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Isosorbide Dinitrate.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Isosorbide Dinitrate.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Isosorbide Dinitrate.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Isosorbide Dinitrate.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Isosorbide Dinitrate.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Isosorbide Dinitrate.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Isosorbide Dinitrate.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Isosorbide Dinitrate.Approved
OlaparibThe metabolism of Isosorbide Dinitrate can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Isosorbide Dinitrate.Approved, Investigational
OsimertinibThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Osimertinib.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Isosorbide Dinitrate.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Isosorbide Dinitrate.Approved, Vet Approved
PalbociclibThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Palbociclib.Approved
PapaverineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Papaverine.Approved
PenbutololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Isosorbide Dinitrate can be increased when combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Isosorbide Dinitrate.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Isosorbide Dinitrate.Approved
PhenobarbitalThe metabolism of Isosorbide Dinitrate can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Isosorbide Dinitrate.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Isosorbide Dinitrate.Approved
PhenytoinThe metabolism of Isosorbide Dinitrate can be increased when combined with Phenytoin.Approved, Vet Approved
PindololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Isosorbide Dinitrate.Approved, Investigational
PosaconazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Isosorbide Dinitrate.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Isosorbide Dinitrate.Approved
PrilocaineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Prilocaine.Approved
PrimidoneThe metabolism of Isosorbide Dinitrate can be increased when combined with Primidone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Isosorbide Dinitrate.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Isosorbide Dinitrate.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Isosorbide Dinitrate.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Isosorbide Dinitrate.Approved
RanolazineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Isosorbide Dinitrate.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Isosorbide Dinitrate.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Isosorbide Dinitrate.Approved, Investigational
RifabutinThe metabolism of Isosorbide Dinitrate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Isosorbide Dinitrate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Isosorbide Dinitrate can be increased when combined with Rifapentine.Approved
RiociguatIsosorbide Dinitrate may increase the hypotensive activities of Riociguat.Approved
RisperidoneIsosorbide Dinitrate may increase the hypotensive activities of Risperidone.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Isosorbide Dinitrate.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Isosorbide Dinitrate.Approved
RosiglitazoneThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Rosiglitazone.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Isosorbide Dinitrate.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Isosorbide Dinitrate.Approved
SaquinavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Isosorbide Dinitrate.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Isosorbide Dinitrate.Approved, Investigational, Vet Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Isosorbide Dinitrate.Approved, Vet Approved
SildenafilThe metabolism of Isosorbide Dinitrate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Simeprevir.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Isosorbide Dinitrate.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Isosorbide Dinitrate.Approved
St. John's WortThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Isosorbide Dinitrate.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Isosorbide Dinitrate.Approved, Investigational
SulfisoxazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TadalafilTadalafil may increase the vasodilatory activities of Isosorbide Dinitrate.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Isosorbide Dinitrate.Approved, Investigational
TelaprevirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Isosorbide Dinitrate can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Telmisartan.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Terazosin.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Isosorbide Dinitrate.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Isosorbide Dinitrate.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Isosorbide Dinitrate.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Isosorbide Dinitrate.Approved, Withdrawn
TiclopidineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Ticlopidine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Isosorbide Dinitrate.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Isosorbide Dinitrate.Approved
TocilizumabThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Isosorbide Dinitrate.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Isosorbide Dinitrate.Approved, Withdrawn
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Isosorbide Dinitrate.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Isosorbide Dinitrate.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isosorbide Dinitrate.Approved
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Isosorbide Dinitrate.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Isosorbide Dinitrate.Approved
UdenafilUdenafil may increase the vasodilatory activities of Isosorbide Dinitrate.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Isosorbide Dinitrate.Approved, Investigational
VardenafilVardenafil may increase the vasodilatory activities of Isosorbide Dinitrate.Approved
VenlafaxineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Isosorbide Dinitrate.Approved
VoriconazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Isosorbide Dinitrate can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Take without regard to meals. Absorption is faster on an empty stomach.

References

Synthesis Reference

Gunter Cordes, Ulrich Munch, Ewald Giesselmann, "Supersaturated isosorbide dinitrate solution, process for its production and its use." U.S. Patent US4156736, issued August, 1976.

US4156736
General References
Not Available
External Links
Human Metabolome Database
HMDB15021
KEGG Drug
D00516
KEGG Compound
C07456
PubChem Compound
6883
PubChem Substance
46506412
ChemSpider
6619
ChEBI
6061
ChEMBL
CHEMBL6622
Therapeutic Targets Database
DAP001057
PharmGKB
PA450125
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
ATC Codes
C05AE02 — Isosorbide dinitrateC01DA58 — Isosorbide dinitrate, combinationsC01DA08 — Isosorbide dinitrate
AHFS Codes
  • 24:12.08 — Nitrates and Nitrites

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Unknown StatusTreatmentAcute Coronary Syndromes (ACS)1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentHeart Failure, Unspecified1
1Unknown StatusTreatmentDuchenne's Muscular Dystrophy (DMD)1
1, 2Active Not RecruitingTreatmentChronic Orthostatic Intolerance / Tachycardia1
2Active Not RecruitingTreatmentCongestive Heart Failure (CHF) / Heart Failure, Unspecified1
3Active Not RecruitingTreatmentAcute Heart Failure (AHF) / Symptomatic left ventricular ejection fraction ≤ 35% Chronic heart failure1
3CompletedTreatmentCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia1
3CompletedTreatmentDiabetic Foot Ulcers (DFU)1
3CompletedTreatmentHeart Failure, Unspecified / Hypertensive1
3Unknown StatusTreatmentCardio-Renal Syndrome1
4CompletedPreventionAdverse Effects / Coronary Artery Atherosclerosis / Insulin resistance syndrome1
4CompletedTreatmentCongestive Heart Failure (CHF)1
4CompletedTreatmentCoronary Artery Stenosis / Coronary Heart Disease (CHD)1
4CompletedTreatmentMaternal Care for Late Fetal Death / Pregnancy, Cornual1
4CompletedTreatmentMyocardial Ischemia / Quality of Life / Stable Angina (SA)1
4RecruitingBasic SciencePost-anesthesia Recovery1
4RecruitingPreventionChronic Hemodialysis (ESRD)1
Not AvailableActive Not RecruitingPreventionCardio-Renal Syndrome1
Not AvailableCompletedHealth Services ResearchBMI >30 kg/m21
Not AvailableNot Yet RecruitingTreatmentHeart Decompensation1
Not AvailableRecruitingNot AvailableHeart Failure, Unspecified1
Not AvailableRecruitingPreventionPancreatitis1
Not AvailableUnknown StatusBasic ScienceCoronary Artery Disease1

Pharmacoeconomics

Manufacturers
  • Alcon laboratories inc
  • Schwarz pharma inc
  • Wyeth ayerst laboratories
  • Astrazeneca pharmaceuticals lp
  • Caraco pharmaceutical laboratories ltd
  • Corepharma llc
  • Biovail laboratories inc
  • Mutual pharmaceutical co inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Superpharm corp
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • West ward inc
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedOral
Tablet, extended releaseOral20 mg
Tablet, extended releaseOral40 mg
CapsuleOral40 mg/1
Capsule, extended releaseOral40 mg/1
TabletOral10 mg
TabletOral30 mg
TabletSublingual5 mg
TabletOral40 mg/1
TabletOral5 mg/1
TabletOral30 mg/1
TabletOral10 mg/1
TabletOral20 mg/1
Tablet, extended releaseOral40 mg/1
TabletSublingual2.5 mg/1
TabletSublingual5 mg/1
Prices
Unit descriptionCostUnit
Isordil Titradose 40 mg tablet1.7USD tablet
Isordil 40 mg tablet1.58USD tablet
Dilatrate-sr 40 mg capsule1.48USD capsule
Isochron 40 mg tablet sa1.07USD tablet
Isosorbide Dinitrate CR 40 mg Controlled Release Tabs0.88USD tab
Isosorbide Mononitrate 20 mg tablet0.78USD tablet
Isosorbide Mononitrate 10 mg tablet0.74USD tablet
Isordil Titradose 5 mg tablet0.68USD tablet
Isordil 5 mg tablet0.65USD tablet
Isosorbide dn 30 mg tablet0.53USD tablet
Isordil 10 mg tablet0.5USD tablet
Isosorbide Dinitrate 30 mg tablet0.5USD tablet
Cedocard-Sr 20 mg Sustained-Release Tablet0.44USD tablet
Isosorbide Dinitrate 10 mg tablet0.43USD tablet
Isosorbide Dinitrate 20 mg tablet0.43USD tablet
Isosorbide Dinitrate 2.5 mg Sublingual Tabs0.39USD tab
Isosorbide Dinitrate 5 mg Sublingual Tabs0.21USD tab
Isosorbide dn 2.5 mg tablet sl0.21USD tablet
Isosorbide dn 5 mg tablet sl0.21USD tablet
Isosorbide dn 20 mg tablet0.2USD tablet
Isosorbide Dinitrate 5 mg tablet0.17USD tablet
Isosorbide dn 10 mg tablet0.17USD tablet
Isosorbide dn 5 mg tablet0.17USD tablet
Apo-Isdn 30 mg Tablet0.09USD tablet
Apo-Isdn 5 mg Sublingual Tablet0.07USD tablet
Apo-Isdn 10 mg Tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6465463No2000-09-082020-09-08Us
US6784177No2000-09-082020-09-08Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)70 °CPhysProp
water solubility550 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.31HANSCH,C ET AL. (1995)
logS-2.63ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.938 mg/mLALOGPS
logP0.87ALOGPS
logP0.44ChemAxon
logS-2.4ALOGPS
pKa (Strongest Basic)-3.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area128.56 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity44.77 m3·mol-1ChemAxon
Polarizability18.07 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.935
Blood Brain Barrier+0.9559
Caco-2 permeable-0.5746
P-glycoprotein substrateNon-substrate0.8064
P-glycoprotein inhibitor INon-inhibitor0.6173
P-glycoprotein inhibitor IINon-inhibitor0.8911
Renal organic cation transporterNon-inhibitor0.8453
CYP450 2C9 substrateNon-substrate0.9057
CYP450 2D6 substrateNon-substrate0.9021
CYP450 3A4 substrateSubstrate0.5298
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9534
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9538
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7116
BiodegradationReady biodegradable0.7633
Rat acute toxicity2.4849 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5057
hERG inhibition (predictor II)Non-inhibitor0.9381
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as isosorbides. These are organic polycyclic compounds containing an isosorbide(1,4-Dianhydrosorbitol) moiety, which consists of two -oxolan-3-ol rings.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Furofurans
Sub Class
Isosorbides
Direct Parent
Isosorbides
Alternative Parents
Tetrahydrofurans / Alkyl nitrates / Organic nitro compounds / Organic nitric acids and derivatives / Oxacyclic compounds / Dialkyl ethers / Organic oxides / Organic nitrogen compounds / Hydrocarbon derivatives
Substituents
Isosorbide / Organic nitrate / Tetrahydrofuran / Alkyl nitrate / Organic nitric acid or derivatives / Organic nitro compound / Dialkyl ether / Ether / Allyl-type 1,3-dipolar organic compound / Organic 1,3-dipolar compound
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
nitrate ester, glucitol derivative (CHEBI:6061)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein kinase activity
Specific Function
Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate ...
Gene Name
NPR1
Uniprot ID
P16066
Uniprot Name
Atrial natriuretic peptide receptor 1
Molecular Weight
118918.11 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Villarroya M, Lopez MG, de Pascual R, Garcia AG: Preclinical profile of PF9404C, a nitric oxide donor with beta receptor blocking properties. Cardiovasc Drug Rev. 2005 Summer;23(2):149-60. [PubMed:16007231]
  4. Takabuchi S, Hirota K, Nishi K, Oda S, Oda T, Shingu K, Takabayashi A, Adachi T, Semenza GL, Fukuda K: The inhibitory effect of sodium nitroprusside on HIF-1 activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway. Biochem Biophys Res Commun. 2004 Nov 5;324(1):417-23. [PubMed:15465035]
  5. Beauregard C, Brandt PC, Chiou GC: Nitric oxide and cyclic GMP-mediated protein secretion from cultured lacrimal gland acinar cells. J Ocul Pharmacol Ther. 2002 Oct;18(5):429-43. [PubMed:12419094]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34